{"aaData": [["VA-WH HIRISK MEDS (EXTREME RISK) PREG RULE", "
Known or Potential Teratogen (FDA Category X)
\n", "
\nTeratogenic Medications Order Check - Category X Meds\n \nDue for: women of childbearing age (10-52) \nExclusions: documented hysterectomy, documented tubal ligation more recent\nthan documented tubal reanastomosis\n
\n
\n", "
NATIONAL
\n", "", "", "
\n
\n\n
\n", "
TESTING
\n", "", "", "
VA-WH HIRISK ORDER CHECK - PREGNANT
\n", "
APPLICABLE
\n", "
BOTH ORDER CHECK AND DEFINITION TEXT
\n", "
MEDIUM
\n", "
\nUse contraindicated during pregnancy, because risks clearly outweigh \nbenefits of treatment (see REPROTOX).\n\\\\ \\\\1) Pregnancy must be excluded prior to receiving this medication. \n\\\\2) Discuss the fetal risks of medication treatment if pregnancy occurs.\n\\\\3) Provide contraceptive counseling and encourage effective\ncontraception.\n\\\\4) Such counseling must be documented in the medical record by the\n\\\\prescriber.\n
\n
\n", "
8
\n", "
8
\n", "
\nUse contraindicated during pregnancy, because risks clearly outweigh benefits\nof treatment (see REPROTOX). \n \n1) Pregnancy must be excluded prior to receiving this medication. \n2) Discuss the fetal risks of medication treatment if pregnancy occurs. \n3) Provide contraceptive counseling and encourage effective contraception. \n4) Such counseling must be documented in the medical record by the \nprescriber.\n
\n
\n"], ["VA-WH HIRISK MEDS (MODERATE/HIGH RISK) PREG RULE", "
Known or Potential Teratogen (FDA Cat. D or Cat. C w/other data)
\n", "
\nTeratogenic Medications Order Check - Category D and selected C Meds \n  \nDue for: women of childbearing age (10-52) \nExclusions: documented hysterectomy, documented tubal ligation more recent\nthan documented tubal reanastomosis\n
\n
\n", "
NATIONAL
\n", "", "", "
\n
\n\n
\n", "
TESTING
\n", "", "", "
VA-WH HIRISK ORDER CHECK - PREGNANT
\n", "
APPLICABLE
\n", "
BOTH ORDER CHECK AND DEFINITION TEXT
\n", "
MEDIUM
\n", "
\nUse during pregnancy increases or may increase the risk for birth\n\\\\prescriber.\n\\\\defects or other adverse pregnancy outcomes (see REPROTOX).\n\\\\ \\\\1) Pregnancy status should be determined. \n\\\\2) Discuss the risks and benefits of medication treatment for a mother\n\\\\and fetus and the risks of untreated disease. Potential treatment\n\\\\benefits may warrant use during pregnancy despite risks.\n\\\\3) Provide contraceptive counseling and encourage effective\n\\\\contraception for patients who are not trying to conceive.\n\\\\4) Such counseling must be documented in the medical record by the\n
\n
\n", "
10
\n", "
11
\n", "
\nUse during pregnancy increases or may increase the risk for birth \n4) Such counseling must be documented in the medical record by the \nprescriber.\ndefects or other adverse pregnancy outcomes (see REPROTOX). \n \n1) Pregnancy status should be determined. \n2) Discuss the risks and benefits of medication treatment for a mother \nand fetus and the risks of untreated disease. Potential treatment \nbenefits may warrant use during pregnancy despite risks. \n3) Provide contraceptive counseling and encourage effective \ncontraception for patients who are not trying to conceive. \n
\n
\n"]]}